Zydus Lifesciences will get USFDA nod for ammonium lactate cream – CNBC TV18 – Company Technique & Outlook

Zydus Lifesciences Ltd. has acquired ultimate approval from the US Meals and Drug Administration (USFDA) for Ammonium Lactate Cream, 12%.

Ammonium lactate cream 12% is a topical prescription medicine indicated for the therapy of dry, scaly pores and skin, often called xerosis, and an inherited dry pores and skin situation known as ichthyosis vulgaris.

It really works by growing pores and skin hydration and, as an alpha-hydroxy acid, helps relieve itching, soften the pores and skin, and cut back scaling.

The product might be manufactured on the group’s topical manufacturing facility in Changodar, Ahmedabad, and distributed in the US by Viona Prescription drugs Inc.

In accordance with IQVIA MAT December 2025 knowledge, ammonium lactate cream recorded annual gross sales of $15 million within the US.

With this, the group now has 430 approvals and has filed 505 ANDAs because it started the submitting course of in FY 2003-04.

Shares of Zydus Lifesciences Ltd. ended 1.57% larger on Friday at ₹906.50. The inventory is flat on a year-to-date foundation.